Duvezin-Caubet
Stephane Duvezin-Caubet, Mimbaste FR
Patent application number | Description | Published |
---|---|---|
20100021955 | MODELLING IN YEAST OF THE MITOCHONDRIAL ATP6 GENE MUTATIONS RESPONSIBLE FOR NARP SYNDROME IN HUMANS AND USES THEREOF FOR SCREENING FOR MEDICAMENTS - Modified yeast cells comprising at least one mutation of the tryptophan 136 (W | 01-28-2010 |
Stéphane Duvezin-Caubet, Pessac FR
Patent application number | Description | Published |
---|---|---|
20100209436 | METHOD FOR TREATING DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION - The present invention relates to means and methods for therapeutic intervention of mitochondrial disorders or diseases, in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial dysfunction, a mitochondrial disorder or disease or a disorder or disease characterized by an altered OPA1 processing. Thereby, a pharmaceutically active amount of a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof is administered to a patient in need of medical intervention. The present invention also relates to the use of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof for the preparation of a pharmaceutical composition for the mentioned therapeutic intervention. The present invention further relates to a method of screening for a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof comprising the use of OPA1. | 08-19-2010 |
Stéphane Duvezin-Caubet, Pessac FR
Patent application number | Description | Published |
---|---|---|
20100209436 | METHOD FOR TREATING DISEASES RELATED TO MITOCHONDRIAL DYSFUNCTION - The present invention relates to means and methods for therapeutic intervention of mitochondrial disorders or diseases, in particular to a method for the treatment, prevention and/or amelioration of a disorder or disease correlated with mitochondrial dysfunction, a mitochondrial disorder or disease or a disorder or disease characterized by an altered OPA1 processing. Thereby, a pharmaceutically active amount of a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof is administered to a patient in need of medical intervention. The present invention also relates to the use of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof for the preparation of a pharmaceutical composition for the mentioned therapeutic intervention. The present invention further relates to a method of screening for a compound capable of modulating the activity of an oligomeric complex comprising Afg3I1 and/or Afg3I2 or (a) variant(s) thereof comprising the use of OPA1. | 08-19-2010 |